TY - JOUR
T1 - Sodium-glucose cotransporter 2 inhibitors at the intersection of cardiovascular, renal and metabolic care
T2 - an integrated and multidisciplinary approach to patient-centered care
AU - Verma, Subodh
AU - Klug, Eric
AU - Mareev, Viacheslav Y.
AU - Kobalava, Zhanna D.
AU - Connelly, Kim A.
AU - Arici, Mustafa
AU - Berwanger, Otávio
AU - Santoso, Anwar
AU - Mehta, Roopa
AU - Meglis, Gus
AU - Kosiborod, Mikhail N.
N1 - Funding Information:
S.V. reports receiving research grants and/or speaking honoraria from Amgen, Amarin, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, EOCI Pharmacomm Ltd, HLS, Janssen, Merck, Novartis, Novo Nordisk, Sanofi, Sun Pharmaceuticals and the Toronto Knowledge Translation Working Group. He is the President of the Canadian Medical and Surgical Knowledge Translation Research Group, a federally incorporated not-for-profit physician organization. S.V. holds a Tier 1 Canada Research Chair in Cardiovascular Surgery, University of Toronto. S.V. wrote the first draft of this article. E.K. reports receiving research grants /speaking honoraria from Amgen, Astra Zeneca, Novartis, Pfizer and Sanofi. V.Y.M. reports receiving research grants and/or speaking honoraria from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, DalCor Pharmaceuticals, Novartis, Novo Nordisk, Pfizer and Servier. Z.D.K. reports receiving speaking honoraria from Astra-Zeneca, Boehringer Ingelheim, Novartis, Novo Nordisk and Sanofi. K.A.C reports research grants to his institution from AstraZeneca and Boehringer Ingelheim, received support for travel to scientific meeting from Boehringer Ingelheim and honoraria for speaking engagements and ad hoc participation in advisory boards from AstraZeneca, Boehringer Ingelheim and Janssen. M.A. reports receiving speaking honoraria from Alexion, Amgen, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Menarini, MSD, Novo Nordisk and Sanofi. O.B. reports receiving research grants and/or participating in advisory boards from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Novartis, Novo Nordisk, Sanofi and Servier. A.S. reports receiving research grants and/or honoraria as a researcher and speaker from the Population Heart Research Institute, ON, Hamilton, Canada and Astra-Zeneca, Boehringer Ingelheim and Pfizer. A.S. is the current President of the ASEAN Federation of Cardiology. R.M. reports receiving research honoraria as a consultant and speaker from Amgen, AstraZeneca, Boehringer Ingel-heim, Eli Lilly, Medix, Novo Nordisk, Sanofi and Silanes. G.M. reports no relevant conflicts of interest. M.K. reports receiving research grants and/or honoraria and/or participating in advisory boards from Amarin, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Eisai, Eli Lilly, GlaxoSmithKline, Glytec, Intarcia, Janssen, Merck (Diabetes), Novartis, Novo Nordisk, Sanofi, Vifor Pharma.
Publisher Copyright:
Copyright 2020 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2020/9/1
Y1 - 2020/9/1
N2 - PURPOSE OF REVIEW: The management of individuals who live with type 2 diabetes requires an integrated and multifaceted approach. RECENT FINDINGS: Sodium-glucose cotransporter 2 inhibitors effectively prevent and treat cardiorenal complications in the presence of type 2 diabetes. They also reduce death and disease progression in those with established heart failure (with reduced ejection fraction) in the absence of diabetes. SUMMARY: Close collaborations between primary care physicians, cardiovascular specialists, endocrinologists and nephrologists are necessary to optimize cardiovascular, renal and metabolic risk reduction in their shared patients.
AB - PURPOSE OF REVIEW: The management of individuals who live with type 2 diabetes requires an integrated and multifaceted approach. RECENT FINDINGS: Sodium-glucose cotransporter 2 inhibitors effectively prevent and treat cardiorenal complications in the presence of type 2 diabetes. They also reduce death and disease progression in those with established heart failure (with reduced ejection fraction) in the absence of diabetes. SUMMARY: Close collaborations between primary care physicians, cardiovascular specialists, endocrinologists and nephrologists are necessary to optimize cardiovascular, renal and metabolic risk reduction in their shared patients.
UR - http://www.scopus.com/inward/record.url?scp=85089301163&partnerID=8YFLogxK
U2 - 10.1097/HCO.0000000000000774
DO - 10.1097/HCO.0000000000000774
M3 - Article
C2 - 32694262
AN - SCOPUS:85089301163
VL - 35
SP - 589
EP - 601
JO - Current Opinion in Cardiology
JF - Current Opinion in Cardiology
SN - 0268-4705
IS - 5
ER -
